Innate Pharma S.A. (IPHA) Discusses IPH4502 Phase 1 Clinical Data and Development Outlook TranscriptSeeking Alpha • Wednesday
Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026Business Wire • Wednesday
Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026Business Wire • 11/11/26
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare ConferenceBusiness Wire • 10/21/26
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial UpdateBusiness Wire • 10/20/26
Down 22% in 4 Weeks, Here's Why Innate Pharma (IPHA) Looks Ripe for a TurnaroundZacks Investment Research • 10/08/26
Down 25% in 4 Weeks, Here's Why You Should You Buy the Dip in Innate Pharma (IPHA)Zacks Investment Research • 10/05/26
Innate Pharma (IPHA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 09/23/26
Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing ConditionsBusiness Wire • 09/16/26
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business UpdateBusiness Wire • 09/10/26
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness Wire • 09/02/26
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement TranscriptSeeking Alpha • 08/14/26
Innate Pharma Jumps as Sobi Deal Boosts Secured Financing for Advancing Rare Skin Cancer TherapyBenzinga • 08/10/26
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphomaPRNewsWire • 08/10/26
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical OfficerBusiness Wire • 08/10/26
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell LymphomaBusiness Wire • 08/10/26